Physical/Mental Wellness
Stanford’s Cartilage Result Is Not a Knee-Replacement Cure. It Is a Better Target.
15-PGDH inhibition is interesting because it appears to reprogram existing cartilage cells, not because it has cured arthritis in people.
The Malaria Headline Is the Baby Drug. The Bigger Story Is the Test That Finds What the Old Test Misses.
The infant formulation closes a lethal dosing gap; the HRP2-deletion-aware diagnostics protect the whole malaria-control stack.
The Gut-Brain Story Just Got More Specific
The Harvard finding does not prove a gut bacterium causes depression. It does something more useful at this stage: it gives the gut-brain hypothesis a molecular mechanism worth testing.
GLP-1 weight loss is fat loss, not muscle loss — read the meta-analysis carefully
A clean meta-analysis just settled one of the two most common GLP-1 objections. Weight loss on semaglutide and tirzepatide is preferentially fat loss, not muscle loss. The clinical implication is...
Kara Swisher's longevity verdict: the boring stuff is the science
When the most-trusted-by-tech journalist of her generation spends a documentary inside the longevity industry and concludes that connection, sleep, and movement are doing more work than any of the sponsored...
Seragon's SRN-901 — a real lifespan number, with a real translation problem
A 33% median lifespan extension in mice is the largest credible published number from a multi-pathway combinatorial in years. Translate it to humans and you are guessing. Read the data,...
The Carelon "ghost network" case just survived — and the payer industry should pay attention
A federal judge let most of the claims survive in a case alleging the systematic misrepresentation of mental-health network adequacy. If the case wins or settles on terms anyone can...
A landmark prenatal-medication and autism study — read it carefully
This is a real, large, peer-reviewed population-level finding that will be cited and contested for the next decade. It is also a study that almost guarantees being misread — by...
Why Ozempic doesn't work for one in ten — and now we can predict who
GLP-1 non-response just stopped being a clinical mystery and started being a measurable diagnostic category. The implications for prior authorisation, prescribing protocol, and patient triage land in 2026, not 2030.
Stanford's "natural Ozempic" is the clearest signal yet of a post-GLP-1 generation
BRP is not a competitor to Ozempic — it is a proof that the appetite-regulation system has multiple modulatable circuits, and that AI peptide discovery just shortened the timeline for...
The "Ozempic personality" is a category, not a side effect
A drug class large enough to reshape the body politic is now reshaping the affective one too. The "Ozempic personality" framing is loose, but the underlying signal — emotional blunting...
The largest US mental-health policy shift in two decades was signed by executive order
The psychedelic executive order is right on direction, wrong on instrument. Treating clinical access expansion as if it were a tariff schedule — fast, unilateral, single-signature — risks burning the...